IL13RA2 and neoplasm: For instance, compared to single-antigen CAR T-cells, dual-targeted CAR T-cells that recognize both EGFRvIII and IL-13Rα2 have demonstrated improved antitumor effectiveness because they can eradicate a variety of tumor cell types.